ACT up +0.59% percent right now. $ACT High is at 247.85 and the Low 242.70 with current volume of 656,146.
Recent News posted below.
ACT Actavis Inc Recent Headline News
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 68.96 (unch), ACT: 246.30 (+0.39), JAZZ: 172.87 (+2.07), UNH: 94.64 (+1.03), CELG: 107.80 (+1.35), CELGZ: 3.17 (-0.07)
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 12:20PM CST
Ironwood reported a loss of 30 cents per share in the third quarter of 2014, narrower than the year-ago loss of 51 cents
ACT: 246.30 (+0.39), VRX: 128.01 (+1.90), IRWD: 13.85 (+0.01), AUXL: 32.74 (-0.01)
Stocks On Indefinite Tack; Rumors See Actavis Merger
at Investor's Business Daily - Thu Nov 06, 11:05AM CST
Stock indexes moved in an indefinite fashion midday Thursday despite speculation that the European Central Bank is moving closer to quantitative easing. The Nasdaq and the S&P 500 shifted 0.1% up and 0.1% down, unable to find traction in either...
AGN: 195.56 (-0.44), ACT: 246.30 (+0.39), MSFT: 48.85 (+0.17), VZ: 51.02 (+0.16)
Company News for November 06, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:10AM CST
Companies in the News are: ACT,CTSH,COV,TW
ACT: 246.30 (+0.39), COV: 92.50 (+0.42), CTSH: 53.73 (+0.11), TW: 114.08 (-0.58)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 195.56 (-0.44), VRX: 128.01 (+1.90), ACT: 246.30 (+0.39), SHPG: 200.39 (+1.81), ABBV: 63.52 (+2.02)
Jim Cramer's Top Stock Picks: LMT MPC ACT
at The Street - Thu Nov 06, 5:00AM CST
Marathon is Cramer's favorite refiner and Actavis is a great drug maker.
LMT: 187.03 (+0.88), ACT: 246.30 (+0.39), MPC: 94.23 (+0.15)
Jim Cramer's 'Mad Money' Recap: What a Republican Senate Means for Stocks
at The Street - Wed Nov 05, 7:20PM CST
It's bullish news but you can't buy just anything, Cramer says.
ACT: 246.30 (+0.39), LMT: 187.03 (+0.88), XOM: 96.45 (-0.14), ILMN: 189.12 (+2.77), AKS: 6.55 (-0.07), KORS: 69.72 (-0.23), PAYX: 47.35 (+0.02), RIG: 29.63 (-0.08), EOG: 99.70 (+0.15), COST: 137.17 (-0.54), TWTR: 40.03 (-0.28), OXY: 88.32 (+0.28), KO: 42.33 (+0.01), SEAS: 18.49 (+0.10), TMO: 117.01 (+0.41), NUE: 53.81 (-0.37), TRIP: 73.11 (-0.54), DISCA: 32.50 (-0.12), CHUY: 22.96 (+0.94), LB: 76.06 (+0.45), GEO: 40.84 (-0.56), ESV: 40.34 (-0.97), MPC: 94.23 (+0.15), BAX: 70.51 (-0.10), MRK: 59.04 (-0.30), EXPE: 85.87 (+0.76), STI: 39.63 (-0.03)
Video: 3 IBD 50 Tech, Drug Stocks With Earnings Thursday
at Investor's Business Daily - Wed Nov 05, 7:01PM CST
Several IBD 50 drug and tech companies release quarterly earnings results on Thursday: Akorn, Salix Pharmaceuticals and Skyworks Solutions. All three have IBD's highest possible Composite Rating, a 99, meaning their shares outperform 99% of all...
AGN: 195.56 (-0.44), ACT: 246.30 (+0.39), SWKS: 61.27 (+1.39), AKRX: 35.47 (-1.12), SLXP: 93.94 (+2.47), AAPL: 108.93 (-0.08)
Actavis Beats Q3 Views As Buyout Talk Swirls
at Investor's Business Daily - Wed Nov 05, 5:45PM CST
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis' (AGN) earnings, excluding one-time...
AGN: 195.56 (-0.44), VRX: 128.01 (+1.90), ACT: 246.30 (+0.39)
Actavis (ACT) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Nov 05, 1:10PM CST
The following Actavis (ACT) conference call took place on November 5, 2014, 08:00 AM ET. This is a transcript of that earnings call:
ACT: 246.30 (+0.39)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 92.88 (+1.82), ACT: 246.30 (+0.39), MYL: 54.16 (+1.05), TEVA: 58.08 (+0.38)
Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza
George Budwell, The Motley Fool - Motley Fool - Wed Nov 05, 8:36AM CST
Healthcare stocks, in general, and biopharmas, in particular, have seen some of their best returns in decades, fueled mainly by a wave of new drugs gaining approval and an aging population in the U.S. The growth story of specialty and generic...
AGN: 195.56 (-0.44), ACT: 246.30 (+0.39), TEVA: 58.08 (+0.38)
Actavis reports 3Q loss
Automated Insights - Wed Nov 05, 6:36AM CST
DUBLIN 2, Ireland (AP) _ Actavis PLC (ACT) on Wednesday reported a third-quarter loss of $1.04 billion.
ACT: 246.30 (+0.39)
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015
PR Newswire - Wed Nov 05, 5:45AM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Chief Financial Officer R. Todd Joyce will retire from Actavis in early 2015. To ensure a smooth transition, the Company said Mr. Joyce will continue as the Company's CFO until a successor is named. Actavis has engaged a leading executive search firm to identify a successor.
ACT: 246.30 (+0.39)
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19
PR Newswire - Wed Nov 05, 5:30AM CST
Actavis plc (NYSE: ACT) today reported net revenue increased 83 percent to $3.7 billion for the third quarter ended September 30, 2014, compared to $2.0 billion in the third quarter 2013. On a non-GAAP basis, diluted earnings per share for the third quarter 2014 increased to $3.19, compared to $2.09 per diluted share in the third quarter 2013. GAAP loss per diluted share for the third quarter 2014 was $3.95, compared to GAAP earnings per share of $0.49 in the prior year period.
ACT: 246.30 (+0.39)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.56 (-0.44), BIIB: 325.85 (+5.10), VRX: 128.01 (+1.90), ACT: 246.30 (+0.39), JAZZ: 172.87 (+2.07), ALXN: 194.24 (+0.43), CELG: 107.80 (+1.35)
Stocks End Mixed; Jazz Pharma Rises After Hours
at Investor's Business Daily - Tue Nov 04, 4:11PM CST
Stocks closed mixed, as earnings reports shook some stocks after the bell. The Nasdaq and S&P 500 dropped 0.3%, and the Dow Jones industrial average gained 0.1%. Volume was higher on the NYSE and lower on the Nasdaq, according to preliminary figures....
TSLA: 242.08 (+1.88), ACT: 246.30 (+0.39), FEYE: 32.45 (+1.83), AWAY: 29.35 (+0.14), CYBR: 34.56 (+1.85), JAZZ: 172.87 (+2.07), TRIP: 73.11 (-0.54), PANW: 109.75 (+2.73), ATHM: 44.33 (+0.70)
Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 92.88 (+1.82), ACT: 246.30 (+0.39), ARIA: 6.28 (+0.20), HSP: 56.03 (-0.29)
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 246.30 (+0.39), ECYT: 6.09 (+0.06), MRK: 59.04 (-0.30), HSP: 56.03 (-0.29)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 109.28 (-3.49), ACT: 246.30 (+0.39), PRGO: 155.99 (+0.22), ALNY: 99.06 (+3.22)
Recent News posted below.
ACT Actavis Inc Recent Headline News
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 68.96 (unch), ACT: 246.30 (+0.39), JAZZ: 172.87 (+2.07), UNH: 94.64 (+1.03), CELG: 107.80 (+1.35), CELGZ: 3.17 (-0.07)
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 12:20PM CST
Ironwood reported a loss of 30 cents per share in the third quarter of 2014, narrower than the year-ago loss of 51 cents
ACT: 246.30 (+0.39), VRX: 128.01 (+1.90), IRWD: 13.85 (+0.01), AUXL: 32.74 (-0.01)
Stocks On Indefinite Tack; Rumors See Actavis Merger
at Investor's Business Daily - Thu Nov 06, 11:05AM CST
Stock indexes moved in an indefinite fashion midday Thursday despite speculation that the European Central Bank is moving closer to quantitative easing. The Nasdaq and the S&P 500 shifted 0.1% up and 0.1% down, unable to find traction in either...
AGN: 195.56 (-0.44), ACT: 246.30 (+0.39), MSFT: 48.85 (+0.17), VZ: 51.02 (+0.16)
Company News for November 06, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:10AM CST
Companies in the News are: ACT,CTSH,COV,TW
ACT: 246.30 (+0.39), COV: 92.50 (+0.42), CTSH: 53.73 (+0.11), TW: 114.08 (-0.58)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 195.56 (-0.44), VRX: 128.01 (+1.90), ACT: 246.30 (+0.39), SHPG: 200.39 (+1.81), ABBV: 63.52 (+2.02)
Jim Cramer's Top Stock Picks: LMT MPC ACT
at The Street - Thu Nov 06, 5:00AM CST
Marathon is Cramer's favorite refiner and Actavis is a great drug maker.
LMT: 187.03 (+0.88), ACT: 246.30 (+0.39), MPC: 94.23 (+0.15)
Jim Cramer's 'Mad Money' Recap: What a Republican Senate Means for Stocks
at The Street - Wed Nov 05, 7:20PM CST
It's bullish news but you can't buy just anything, Cramer says.
ACT: 246.30 (+0.39), LMT: 187.03 (+0.88), XOM: 96.45 (-0.14), ILMN: 189.12 (+2.77), AKS: 6.55 (-0.07), KORS: 69.72 (-0.23), PAYX: 47.35 (+0.02), RIG: 29.63 (-0.08), EOG: 99.70 (+0.15), COST: 137.17 (-0.54), TWTR: 40.03 (-0.28), OXY: 88.32 (+0.28), KO: 42.33 (+0.01), SEAS: 18.49 (+0.10), TMO: 117.01 (+0.41), NUE: 53.81 (-0.37), TRIP: 73.11 (-0.54), DISCA: 32.50 (-0.12), CHUY: 22.96 (+0.94), LB: 76.06 (+0.45), GEO: 40.84 (-0.56), ESV: 40.34 (-0.97), MPC: 94.23 (+0.15), BAX: 70.51 (-0.10), MRK: 59.04 (-0.30), EXPE: 85.87 (+0.76), STI: 39.63 (-0.03)
Video: 3 IBD 50 Tech, Drug Stocks With Earnings Thursday
at Investor's Business Daily - Wed Nov 05, 7:01PM CST
Several IBD 50 drug and tech companies release quarterly earnings results on Thursday: Akorn, Salix Pharmaceuticals and Skyworks Solutions. All three have IBD's highest possible Composite Rating, a 99, meaning their shares outperform 99% of all...
AGN: 195.56 (-0.44), ACT: 246.30 (+0.39), SWKS: 61.27 (+1.39), AKRX: 35.47 (-1.12), SLXP: 93.94 (+2.47), AAPL: 108.93 (-0.08)
Actavis Beats Q3 Views As Buyout Talk Swirls
at Investor's Business Daily - Wed Nov 05, 5:45PM CST
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis' (AGN) earnings, excluding one-time...
AGN: 195.56 (-0.44), VRX: 128.01 (+1.90), ACT: 246.30 (+0.39)
Actavis (ACT) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Nov 05, 1:10PM CST
The following Actavis (ACT) conference call took place on November 5, 2014, 08:00 AM ET. This is a transcript of that earnings call:
ACT: 246.30 (+0.39)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 92.88 (+1.82), ACT: 246.30 (+0.39), MYL: 54.16 (+1.05), TEVA: 58.08 (+0.38)
Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza
George Budwell, The Motley Fool - Motley Fool - Wed Nov 05, 8:36AM CST
Healthcare stocks, in general, and biopharmas, in particular, have seen some of their best returns in decades, fueled mainly by a wave of new drugs gaining approval and an aging population in the U.S. The growth story of specialty and generic...
AGN: 195.56 (-0.44), ACT: 246.30 (+0.39), TEVA: 58.08 (+0.38)
Actavis reports 3Q loss
Automated Insights - Wed Nov 05, 6:36AM CST
DUBLIN 2, Ireland (AP) _ Actavis PLC (ACT) on Wednesday reported a third-quarter loss of $1.04 billion.
ACT: 246.30 (+0.39)
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015
PR Newswire - Wed Nov 05, 5:45AM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Chief Financial Officer R. Todd Joyce will retire from Actavis in early 2015. To ensure a smooth transition, the Company said Mr. Joyce will continue as the Company's CFO until a successor is named. Actavis has engaged a leading executive search firm to identify a successor.
ACT: 246.30 (+0.39)
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19
PR Newswire - Wed Nov 05, 5:30AM CST
Actavis plc (NYSE: ACT) today reported net revenue increased 83 percent to $3.7 billion for the third quarter ended September 30, 2014, compared to $2.0 billion in the third quarter 2013. On a non-GAAP basis, diluted earnings per share for the third quarter 2014 increased to $3.19, compared to $2.09 per diluted share in the third quarter 2013. GAAP loss per diluted share for the third quarter 2014 was $3.95, compared to GAAP earnings per share of $0.49 in the prior year period.
ACT: 246.30 (+0.39)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.56 (-0.44), BIIB: 325.85 (+5.10), VRX: 128.01 (+1.90), ACT: 246.30 (+0.39), JAZZ: 172.87 (+2.07), ALXN: 194.24 (+0.43), CELG: 107.80 (+1.35)
Stocks End Mixed; Jazz Pharma Rises After Hours
at Investor's Business Daily - Tue Nov 04, 4:11PM CST
Stocks closed mixed, as earnings reports shook some stocks after the bell. The Nasdaq and S&P 500 dropped 0.3%, and the Dow Jones industrial average gained 0.1%. Volume was higher on the NYSE and lower on the Nasdaq, according to preliminary figures....
TSLA: 242.08 (+1.88), ACT: 246.30 (+0.39), FEYE: 32.45 (+1.83), AWAY: 29.35 (+0.14), CYBR: 34.56 (+1.85), JAZZ: 172.87 (+2.07), TRIP: 73.11 (-0.54), PANW: 109.75 (+2.73), ATHM: 44.33 (+0.70)
Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 92.88 (+1.82), ACT: 246.30 (+0.39), ARIA: 6.28 (+0.20), HSP: 56.03 (-0.29)
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 246.30 (+0.39), ECYT: 6.09 (+0.06), MRK: 59.04 (-0.30), HSP: 56.03 (-0.29)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 109.28 (-3.49), ACT: 246.30 (+0.39), PRGO: 155.99 (+0.22), ALNY: 99.06 (+3.22)
